Which Should Be the Control Arm in Trials of Antiplatelet Therapies?

Since the first notification of its existence, the interventionalists have been waiting for this promising drug with the hope of having found an agent that would offer the ideal characteristics of to avoid the need of preloading and also to allow reversibility based on a short half-life.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2015-08, Vol.116 (3), p.493-494
Hauptverfasser:	Lozano, Iñigo, MD, PhD, Rondan, Juan, MD, PhD, Vegas, Jose M., MD, Segovia, Eduardo, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Monophosphate - analogs & derivatives Advisory Committees Cardiovascular Congresses as Topic Coronary Disease - drug therapy Drug Approval - organization & administration Humans Medical imaging Prescription drugs United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Since the first notification of its existence, the interventionalists have been waiting for this promising drug with the hope of having found an agent that would offer the ideal characteristics of to avoid the need of preloading and also to allow reversibility based on a short half-life.
ISSN:	0002-9149 1879-1913
DOI:	10.1016/j.amjcard.2015.05.033